Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Seizures Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Seizures Overview | 13 | 1 |
| Pipeline Products for Seizures Comparative Analysis | 14 | 1 |
| Seizures Therapeutics under Development by Companies | 15 | 3 |
| Seizures Therapeutics under Investigation by Universities/Institutes | 18 | 1 |
| Seizures Pipeline Products Glance | 19 | 4 |
| Late Stage Products | 19 | 1 |
| Clinical Stage Products | 20 | 1 |
| Early Stage Products | 21 | 1 |
| Unknown Stage Products | 22 | 1 |
| Seizures Products under Development by Companies | 23 | 4 |
| Seizures Products under Investigation by Universities/Institutes | 27 | 1 |
| Seizures Companies Involved in Therapeutics Development | 28 | 28 |
| Adamas Pharmaceuticals, Inc. | 28 | 1 |
| Advicenne | 29 | 1 |
| Alexza Pharmaceuticals, Inc. | 30 | 1 |
| Biscayne Pharmaceuticals, Inc. | 31 | 1 |
| Catalyst Pharmaceuticals, Inc. | 32 | 1 |
| Eisai Co., Ltd. | 33 | 1 |
| GW Pharmaceuticals Plc | 34 | 1 |
| INSYS Therapeutics, Inc. | 35 | 1 |
| Lotus Pharmaceutical Co., Ltd. | 36 | 1 |
| Marinus Pharmaceuticals, Inc. | 37 | 1 |
| Neurelis, Inc. | 38 | 1 |
| Novartis AG | 39 | 1 |
| OPKO Health, Inc. | 40 | 1 |
| Pfizer Inc. | 41 | 1 |
| PTC Therapeutics, Inc. | 42 | 1 |
| Sage Therapeutics, Inc. | 43 | 1 |
| SciFluor Life Sciences, LLC | 44 | 1 |
| Shire Plc | 45 | 1 |
| SK Biopharmaceuticals Co., Ltd. | 46 | 1 |
| Suda Ltd | 47 | 1 |
| Turing Pharmaceuticals AG | 48 | 1 |
| UCB S.A. | 49 | 1 |
| Ultragenyx Pharmaceutical Inc. | 50 | 1 |
| Upsher-Smith Laboratories, Inc. | 51 | 1 |
| Xenon Pharmaceuticals Inc. | 52 | 1 |
| XERIS Pharmaceuticals, Inc. | 53 | 1 |
| Zogenix, Inc. | 54 | 1 |
| Zynerba Pharmaceuticals, Inc. | 55 | 1 |
| Seizures Therapeutics Assessment | 56 | 13 |
| Assessment by Monotherapy Products | 56 | 1 |
| Assessment by Target | 57 | 4 |
| Assessment by Mechanism of Action | 61 | 4 |
| Assessment by Route of Administration | 65 | 2 |
| Assessment by Molecule Type | 67 | 2 |
| Drug Profiles | 69 | 127 |
| ADS-4101 Drug Profile | 69 | 1 |
| ADV-6208 Drug Profile | 70 | 1 |
| ADV-6770 Drug Profile | 71 | 1 |
| alprazolam Drug Profile | 72 | 2 |
| AMPX-0079 Drug Profile | 74 | 1 |
| ataluren Drug Profile | 75 | 8 |
| BIS-001 Drug Profile | 83 | 1 |
| brivaracetam Drug Profile | 84 | 4 |
| cannabidiol Drug Profile | 88 | 6 |
| cannabidiol Drug Profile | 94 | 2 |
| CCG-63802 Drug Profile | 96 | 1 |
| CHEC-9 Drug Profile | 97 | 1 |
| clobazam Drug Profile | 98 | 1 |
| CNSA-004 Drug Profile | 99 | 1 |
| CPP-115 Drug Profile | 100 | 4 |
| CUR-1916 Drug Profile | 104 | 1 |
| diazepam Drug Profile | 105 | 2 |
| diazepam Drug Profile | 107 | 1 |
| everolimus Drug Profile | 108 | 11 |
| fenfluramine hydrochloride Drug Profile | 119 | 3 |
| fosphenytoin sodium Drug Profile | 122 | 1 |
| ganaxolone Drug Profile | 123 | 5 |
| lacosamide Drug Profile | 128 | 9 |
| levetiracetam Drug Profile | 137 | 3 |
| levetiracetam ER Drug Profile | 140 | 1 |
| lorazepam Drug Profile | 141 | 1 |
| LSPGR-1 Drug Profile | 142 | 1 |
| magnesium valproate hydrate Drug Profile | 143 | 1 |
| MB-003 Drug Profile | 144 | 1 |
| midazolam hydrochloride Drug Profile | 145 | 3 |
| midazolam hydrochloride Drug Profile | 148 | 1 |
| midazolam hydrochloride Drug Profile | 149 | 1 |
| midazolam hydrochloride Drug Profile | 150 | 1 |
| Oligonucleotide for Dravet Syndrome Drug Profile | 151 | 1 |
| perampanel Drug Profile | 152 | 7 |
| pregabalin Drug Profile | 159 | 4 |
| SAGE-217 Drug Profile | 163 | 2 |
| SAGE-689 Drug Profile | 165 | 1 |
| selurampanel Drug Profile | 166 | 1 |
| sepranolone Drug Profile | 167 | 7 |
| SF-0034 Drug Profile | 174 | 2 |
| Small Molecule for Stroke and Epilepsy Drug Profile | 176 | 1 |
| Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders Drug Profile | 177 | 1 |
| Small Molecule to Block Nav1.6 for Dravet Syndrome Drug Profile | 178 | 1 |
| Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus Drug Profile | 179 | 1 |
| Small Molecules for Seizure Disorders Drug Profile | 180 | 1 |
| Small Molecules for Seizures Drug Profile | 181 | 1 |
| TG-4155 Drug Profile | 182 | 1 |
| TRP-001 Drug Profile | 183 | 1 |
| TUR-004 Drug Profile | 184 | 1 |
| TUR-005 Drug Profile | 185 | 1 |
| UX-007 Drug Profile | 186 | 5 |
| YKP-3089 Drug Profile | 191 | 2 |
| ZYN-002 Drug Profile | 193 | 3 |
| Seizures Dormant Projects | 196 | 3 |
| Seizures Discontinued Products | 199 | 1 |
| Seizures Product Development Milestones | 200 | 13 |
| Featured News &Press Releases | 200 | 1 |
| Jul 04, 2016: UCB and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VIMPAT) as adjunctive therapy in the treatment of partial-onset seizures in adult patients with epilepsy | 200 | 1 |
| Jun 28, 2016: Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent BIS-001 AT EILAT Conference On New Antiepileptic Drugs | 200 | 1 |
| Jun 28, 2016: Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent BIS-001 AT EILAT Conference On New Antiepileptic Drugs | 201 | 1 |
| Jun 27, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome | 202 | 2 |
| Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures | 204 | 1 |
| Jun 22, 2016: Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV | 205 | 1 |
| Jun 16, 2016: Eisai Launches New Oral Suspension Formulation For Antiepileptic Drug Fycompa (Perampanel) In The United States | 206 | 1 |
| Jun 13, 2016: Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures | 206 | 1 |
| Jun 13, 2016: Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures | 207 | 1 |
| Jun 13, 2016: Lotus ANDA Of Levetiracetam ER Tablets Has Been Officially Approved By US FDA | 208 | 1 |
| Jun 07, 2016: Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome | 208 | 1 |
| Jun 07, 2016: Sage Reports Positive Top-line Results from Phase 1 Clinical Program of SAGE-217 | 209 | 1 |
| May 31, 2016: BRIVIACT now available in U.S. pharmacies for epilepsy patients living with partial-onset seizures | 210 | 1 |
| May 26, 2016: New epilepsy treatment BRIVLERA (brivaracetam) now available in Canada for patients with partial-onset seizures | 211 | 1 |
| May 25, 2016: Eisai To Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) As Adjunctive Therapy For Partial-Onset And Generalized Tonic-Clonic Seizures In Japan | 211 | 2 |
| Appendix | 213 | 2 |
| Methodology | 213 | 1 |
| Coverage | 213 | 1 |
| Secondary Research | 213 | 1 |
| Primary Research | 213 | 1 |
| Expert Panel Validation | 213 | 1 |
| Contact Us | 213 | 1 |
| Disclaimer | 214 | 1 |